Aktiebolaget Hassle

Other

Aktiebolaget Astra

Conny B Bogentoft

Curt H Appelgren

Karl A Folkers

Jaw-Kang Chang

John A Sjogren

Bruce L Currie

Hans Sievertsson

Gunnar H Ekenved

According to the present invention an oral pharmaceutical preparation of acetylsalicylic acid is provided which consists of cores containing acetylsalicylic acid as pharmaceutically active component, which cores are coated with a polymer membrane to the formation of coated granules. The preparation is characterized in that the polymer membrane comprises at least one polymer selected from the group consisting of cellulose acetate phtalate and methyl esterified methacrylic acid polymers having a degree of esterification of 45-55%, whereby the amount of such polymer forms 60-45% of the weight of the membrane, and at least one methyl esterified methacrylic acid polymer having a degree of esterification of 65-75% and forming 45-25% of the weight of the membrane, and a plasticizer selected from fatty alcohols and fatty acids forming 4-12% of the weight of the membrane, whereby the membrane represents 5-12 weight % of the composition. With this composition a reduced effect on the gastric mucosa as compared with previously known preparations but retaining good absorbtion properties and a controlled release.

Pharmaceutical preparation

A method of preparing a preparation made up by bodies comprising an active component in decreasing concentration towards the surface of the bodies. The method comprises coating a particle with a composition comprising the active component in a continuous coating operation whereby the concentration of the active component is decreased. The active component may be a drug, a pesticide or an agent having some other effect.

Granule having controlled release properties

Method for preparing preparations having controlled release of an active

A solid pharmaceutical preparation for administration in dosage unit form comprising a therapeutically effective cardiac glycoside, whereby each dosage unit is to comprise a plurality of bodies, each of said bodies having a pharmaceutically indifferent core, a first layer thereon containing the glycoside and a second layer containing a polymer insoluble in gastric juice and soluble in intestinal juice, a process for preparing such preparation and a method of treatment employing the same.

Pharmaceutical preparation comprising a cardiac glycoside with a polymer

A solid pharmaceutical preparation for administration in dosage unit form comprising a therapeutically effective cardiac glycoside, whereby each dosage unit is to comprise a plurality of bodies, each of said bodies having a pharmaceutically inert core and a layer thereon containing the glycoside and a polymer insoluble in gastric juice and soluble in intestinal juice, a process for preparing such preparation and a method of treatment employing the same.

Pharmaceutically preparation comprising a cardiac glycoside in

A synthetic decapeptide, L-pglutamyl-L-histidyl-L-tryptophanyl-L-seryl-L-tyrosyl-glycyl-L-leucyl-L- arginyl-L-prolyl-glycinamide which has the hormonal activities of the luteinizing hormone releasing hormone (LRH) of the hypothalamus gland of mammals is produced by utilizing as the key starting materials, the amino acids, glutamic acid or pyroglutamic acid, histidine, tryptophan, serine, tyrosine, glycine, leucine, arginine, and proline. Synthesis of the decapeptide is accomplished by coupling, in appropriate combinations of appropriate protected forms of the amino acids, and finally deprotecting to yield the amide, L-pglutamyl-L-histidyl-L-tryptophanyl-L-seryl-L-tyrosyl-glycyl-L-leucyl-L- arginyl-L-prolyl-glycinamide.

Growing community of inventors

Molndal, Sweden

Conny B Bogentoft